LISA BOMGAARS to Neoplasms
This is a "connection" page, showing publications LISA BOMGAARS has written about Neoplasms.
Connection Strength
0.428
-
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007 Oct 10; 25(29):4622-7.
Score: 0.097
-
Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors. Pediatr Blood Cancer. 2006 Aug; 47(2):163-8.
Score: 0.089
-
A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer. 2006 Jan; 46(1):50-5.
Score: 0.086
-
The development of camptothecin analogs in childhood cancers. Oncologist. 2001; 6(6):506-16.
Score: 0.061
-
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol. 2009 Jul; 64(2):243-51.
Score: 0.026
-
Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. Cancer Chemother Pharmacol. 2008 Nov; 62(6):1027-37.
Score: 0.025
-
Pharmacogenetics and pediatric cancer. Cancer J. 2005 Jul-Aug; 11(4):314-23.
Score: 0.021
-
Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004 Nov 01; 22(21):4394-400.
Score: 0.020
-
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001 Apr 15; 19(8):2293-301.
Score: 0.004